BHP Group Ltd (ASX: BHP) shares are climbing higher into the green again in Tuesday morning trade.

At the time of writing, the shares are up around 1% and changing hands for a new all-time high of $67.88 a piece.

Today’s increase means the ASX mining giant’s shares have now jumped around 13% over the past month alone and up 48% for the year-to-date.

For context, at the time of writing, the S&P/ASX 200 Index (ASX: XJO) is up around 3% over the past month and around 5% higher for the year-to-date.

The latest rally is supported by the miner’s record FY26 earnings results, which it posted to the ASX a week ago. 

The group posted a strong operational performance across all its key segments and an impressive 27% increase in its underlying EBITDA. 

Investors were clearly thrilled with the results and many are rushing to buy the mining shares before they climb even higher.

So, if I bought $6,000 of BHP shares 12 months ago, what would it be worth today?

BHP shares were trading at $43.14 this time last year, and have climbed around 56% higher to the time of writing.

That means a $6,000 investment in the mining giant 12 months ago would be worth a huge $9.360 today!

Can the miner’s shares keep climbing higher?

After a strong rally through 2026 so far, it looks like BHP shares have now reached a ceiling. In fact, some think that the stock is now trading above fair value and could be due a correction.

Market Index data shows that the majority of brokers have a hold rating on the mining shares. But the $61.78 average target price implies a 9% downside ahead.

TradingView data shows something similar. Again the majority (13 out of 23) have a hold rating on BHP shares, but another six have a strong buy rating and four rate the stock as a sell/strong sell.

The average $62.68 target price now implies a potential 8% downside ahead over the next 12 months. But the range between the maximum and the minimum is huge.

Some think the shares have the potential to fall 36% to $43.72, at the time of writing. Meanwhile, more bearish analysts think BHP shares could jump 35% higher to $91.71 within the next 12 months. 

John Athanasiou from Red Leaf Securities has a hold rating on BHP shares following the FY26 results announcement last week. He said that the quality of BHP’s asset base, balance sheet and diversified portfolio leaves existing shareholders with little reason to sell. But, after a solid run, he said investors may be better off waiting for a more attractive entry point.

Morgan Stanley renewed its buy rating on BHP shares after the miner’s FY26 report and increased its 12-month price target to $67.50.

Elsewhere, Morgans has a trim rating and lowered its 12-month price target to $55.30. The broker said the share price already factors in more upside.

The post $6,000 invested in BHP shares 12 months ago is now worth…. appeared first on The Motley Fool Australia.

More reading

• BHP share price hits new record high
• VGS vs VHY: Which Vanguard ETF comes out on top?
• With profits surging to $13.7 billion, are BHP shares a buy, hold or sell now?
• BHP shares just hit a record high. Can the run continue?
• Buy, hold, sell: CSL, BHP, Westpac shares

Motley Fool contributor Samantha Menzies has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Coles Group Ltd (ASX: COL), Ramelius Resources Ltd (ASX: RMS), and Woodside Energy Group Ltd (ASX: WDS) shares are turning heads today.

In late morning trade on Tuesday, all three of the high-profile ASX shares are outpacing the 0.5% gains posted by the S&P/ASX 200 Index (ASX: XJO) at this time.

Here’s what’s catching investor interest.

Woodside shares jump on profit growth

Woodside shares are up 2.5% at the time of writing, changing hands for $34.28 apiece.

This strong performance follows the release of the ASX 200 energy stock’s half-year results (H1 2026).

Highlights for the six months included a 13% year-on-year increase in operating revenue to US$7.45 billion. And the company’s free cash flow was up 159% to US$352 million.

On the bottom line, Woodside achieved a 27% increase in net profit after tax (NPAT) to US$1.67 billion.

This saw management declare a fully-franked interim dividend of 57 US cents per Woodside share.

On the growth project front, Woodside’s Scarborough is 98% complete and on track for first LNG cargo in Q4 2026. Its Trion project is 64% complete, while the Louisiana LNG project is 28% complete.

Woodside ended the half with liquidity of US$8.19 billion.

Ramelius Resources shares lift on gold resource increase

Like Woodside shares, Ramelius Resources shares are marching higher, up 1% at $4.05 each.

This comes after the ASX 200 gold stock reported a 79% increase in its Ore Reserves to 4.3 million ounces of gold. The miner’s Mineral Resources increased by 17% to 14 million ounces.

Ramelius credited the boost to its FY 2026 exploratory drilling campaign, which added 1.8 million ounces of new discovery gold at an average cost of $55 per ounce.

The lift was primarily delivered by the maiden 1.6-million-ounce Ore Reserve at Ramelius’ Never Never underground project, as well as 260,000 ounces at its Roe underground project.

Which brings us to…

Coles shares edge higher on dividend boost

Joining Ramelius Resources and Woodside shares in turning heads today, we find Coles.

Shares in the ASX 200 supermarket giant are up 0.6% at the time of writing, trading for $22.78 apiece.

This follows the release of Coles’ FY 2026 results.

Highlights for the financial year include a 2.8% year-on-year increase in sales revenue to $45.58 billion. Earnings before interest and tax (EBIT) of $2.32 billion (excluding significant items) were up 9.9%.

On the bottom line, Coles achieved a 13.7% year-on-year increase in net profit after tax (NPAT) to $1.26 billion (excluding significant items).

This saw management declare a 37-cent per share fully-franked final dividend, up 15% from last year’s final payout.

If you want to bank the final Coles dividend, you’ll need to own shares at market close on 2 September. Coles shares trade ex-dividend on 3 September.

The post Why is everyone talking about Coles, Ramelius Resources and Woodside shares on Tuesday? appeared first on The Motley Fool Australia.

More reading

• How many Coles shares do I need to buy for $5,000 a year in passive income?
• Coles Group grows profit and dividend as Supermarkets shine in FY26
• Woodside Energy half-year results: US$1,672 million profit and 57 US cents dividend
• Ramelius Resources share price on watch amid 79% surge in Ore Reserves
• 5 things to watch on the ASX 200 on Tuesday

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Cyclopharm Ltd (ASX: CYC) are down almost 50% over the past 12 months, but according to the analysts at Bell Potter, now could be a great time to buy in.

Bell Potter has a buy recommendation on the shares and a bullish price target, which I’ll get to shortly.

First, let’s have a look at the company’s recently released first-half results.

US market primed for growth

Cyclopharm’s flagship product is Technegas, which is a broad-spectrum diagnostic lung imaging technology for the visualisation of pulmonary ventilation and lung function.

The company said Technegas was now available in 67 countries, with more than five million patient procedures to date.

In the first half of 2026, Cyclopharm generated revenue of $17.5 million, up 14% on the same period last year, while revenue growth in the US jumped 74% to $2.1 million.

The company had $12.2 million in cash at the end of June, and posted a net loss of $8.8 million, compared with $7.7 million for the same period last year.

The company explained:

The movement reflects three factors: continued investment in US commercial operations; a near-doubling of research and development expenditure to $0.57 million as we advance our Beyond PE clinical programs; and the absence of the $1.1 million share of joint venture profit recorded in the pcp following the divestment of the non-core Cyclotek interest. Encouragingly, gross margin improved from 53.5% to 56.3%, reflecting the growing weighting of higher-margin Technegas revenue, and particularly US revenue, in the sales mix.

In terms of the market opportunity, Cyclopharm estimates the US market could be worth US$180 million.

Managing Director James McBrayer said:

The US is the world’s largest healthcare market and represents a potential US$180 million annual revenue opportunity for Cyclopharm in the diagnosis and management of Pulmonary Embolism alone. That potential is not speculative; it is built on the same adoption curve that has played out in each of our established markets, where Technegas commands an 85% or greater share of nuclear medicine ventilation imaging. Applying that experience, the Company sees its primary US market as approximately 2,000-site addressable market out of the 5,139 US sites performing nuclear medicine lung imaging, per CMS data. With 70 sites generating revenue as at 30 June 2026, we have only just started.

ASX biotech shares looking cheap

Bell Potter said in its note to clients that the growth was encouraging and noted that half of the top 20 hospitals in the US had now adopted Technegas.

The broker has a $1 price target on Cyclopharm shares compared to 50.5 cents currently.

The company is valued at $63.5 million.

The post Bell Potter says this ASX biotech could nearly double in value appeared first on The Motley Fool Australia.

More reading

• Why is everyone talking about Coles, Ramelius Resources and Woodside shares on Tuesday?
• Buy, hold, sell: DigiCo Infrastructure REIT, CBA, Telstra shares
• 3 amazing ASX ETFs for Aussie investors in September
• How many Coles shares do I need to buy for $5,000 a year in passive income?
• How much do I need in my superannuation to retire comfortably at age 60?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.